‘Itty bitty’ falloposcope imaging device used inside fallopian tubes for the first time

University of Arizona BIO5 Institute Director Jennifer Barton developed the high-resolution falloposcope. [Photo courtesy of the University of Arizona]

After years of development, University of Arizona researchers have captured their first images inside fallopian tubes with a new device that could be used to search for early signs of ovarian cancer before it spreads.

University of Arizona BIO5 Institute Director Jennifer Barton developed the high-resolution falloposcope, which has a diameter of only 0.8 mm.

“It’s itty bitty,” she said in a news release. “You just couldn’t have fabricated something like this, even six, seven years ago.”

Dr. John Heusinkveld has used the falloposcope since September to look inside the fallopian tubes of four volunteers who were having their tubes removed for non-cancer reasons.

“This is the first endoscope that can fi…

Read more
  • 0

Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer

The biopharmaceutical company IMV (NSDQ:IMV) has recently revealed promising data related to its lead immunotherapy as a potential ovarian cancer treatment. In the Phase 2 DeCidE1 trial, the immunotherapy DPX-Survivac with intermittent low-dose cyclophosphamide showed durable anti-tumor activity in patients with recurrent, advanced ovarian cancer.

To learn more about DPX-Survivac’s potential, we reached out to IMV Chief Medical Officer Joanne Schindler. In the following interview, Schindler touches on the standard of care for treating recurrent ovarian cancer and provides an overview of the potential of the T-cell immunotherapy for treating a range of cancers.

Could you highlight some of the main challenges in treating recurrent ovarian cancer? 

Schindler: In recurrent ovarian cancer, platinum-based chemotherapy is the standard of care option for patients who have responded to prior platinum therapy and for whom recurrence was not rapid (e.g., >…

Read more
  • 0